Technical Analysis for RLMD - Relmada Therapeutics Inc

Grade Last Price % Change Price Change
grade B 2.6 -0.38% -0.0100
RLMD closed down 0.38 percent on Friday, September 27, 2019, on 2.2 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical RLMD trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -0.38%
1,2,3 Pullback Bullish Bullish Swing Setup -0.38%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.38%
Down 3 Days in a Row Weakness -0.38%

Older signals for RLMD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.
Biotechnology RTT Euphoriants Drugs Pain Psychoactive Drugs Diseases Depression Opioids Opioid Analgesic Drug Products Buprenorphine Neuropathic Pain Chemical Entities Methadone
Is RLMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.418
52 Week Low 1.01
Average Volume 28,762
200-Day Moving Average 1.8956
50-Day Moving Average 2.3961
20-Day Moving Average 2.7327
10-Day Moving Average 2.7904
Average True Range 0.1594
ADX 36.74
+DI 14.8347
-DI 23.009
Chandelier Exit (Long, 3 ATRs ) 2.4618
Chandelier Exit (Short, 3 ATRs ) 2.6882
Upper Bollinger Band 2.9601
Lower Bollinger Band 2.5053
Percent B (%b) 0.21
BandWidth 16.642881
MACD Line 0.0871
MACD Signal Line 0.1289
MACD Histogram -0.0418
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.0500
Resistance 3 (R3) 3.0333 2.8667 2.9750
Resistance 2 (R2) 2.8667 2.7521 2.8750 2.9500
Resistance 1 (R1) 2.7333 2.6813 2.6500 2.7500 2.9250
Pivot Point 2.5667 2.5667 2.5250 2.5750 2.5667
Support 1 (S1) 2.4333 2.4521 2.3500 2.4500 2.2750
Support 2 (S2) 2.2667 2.3813 2.2750 2.2500
Support 3 (S3) 2.1333 2.2667 2.2250
Support 4 (S4) 2.1500